STRO

#2802
Sutro Biopharma, Inc.
34.6900 USD
+3.27%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
34.6900
34.6900
1年のレンジ
16.7400
36.0000
1日の変化
+3.27%
月次変化
+42.00%
6か月変化
+99.48%
1年の変化
+99.48%
以前の終値
33.5900
始値
34.6900
安値
34.6900
High
34.6900
ボリューム
15
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 574.7175 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-0.51
売上高対価格比率
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

ニュース